Abiopharma

Clinical trial NCT06598306: primary completion date: 2027-03-03 → 2027-04-24.

Clinical trial NCT07023341: completion date: 2028-05-30 → 2028-04-28.

Clinical trial NCT06229834: primary completion date: 2026-04-01 → 2027-04-01.

Clinical trial NCT07154901 updates: 1. status: ACTIVE_NOT_RECRUITING → COMPLETED 2. enrollment: 34 → 35 participants

Clinical trial NCT03152669 updates: 1. status: RECRUITING → TERMINATED 2. completion date: 2028-04-30 → 2025-07-05 3. primary completion date: 2028-04-30 → 2025-07-05 4. enrollment: 3500 → 1183 participants 5. enrollment type: ESTIMATED → ACTUAL

Clinical trial NCT03832361: collaborators added: AbbVie.

Curis Announces Eleven Active Clinical Sites in TakeAim CLL Study, Reaffirms Patient Dosing Guidance, and Reports Stockholder Approval of Reverse Stock Split

Clinical trial NCT06846281: start date: 2025-07-23 → 2025-06-23.

Clinical trial NCT06501092 updates: 1. completion date: 2026-07-31 → 2027-07-31 2. primary completion date: 2026-07-31 → 2027-07-31

Clinical trial NCT06045988 updates: 1. start date: 2026-02-01 → 2026-07-01 2. completion date: 2026-08-01 → 2026-12-01 3. primary completion date: 2026-08-01 → 2026-12-01